BioregulatorsResearch profile

Livagen

Lys-Glu-Asp-Ala · KEDA · Liver bioregulator

Think of it as a tune-up for your liver's genetic machinery.

Livagen is like a personal trainer for your liver cells. It's a small peptide that aims to help your liver function more efficiently by interacting with the genetic material inside your liver cells. Imagine giving your liver a gentle push to keep running smoothly as you age.

This peptide doesn't just stop at the liver. Some studies suggest it might also influence certain immune cells by loosening up tightly packed DNA, potentially waking up genes that have dozed off over time. It's a bit like opening a book that's been closed for a while and finding new chapters to read.

While early research shows promise, Livagen is still mostly in the experimental phase. It's not yet approved for medical use, so it's more of an intriguing possibility than a guaranteed solution.

Who it's for

Biohackers curious about anti-aging strategies
Anyone interested in experimental liver health support
Science enthusiasts tracking peptide research

Probably not for you if…

Those looking for FDA-approved treatments
People who prefer traditional medicine
Anyone uncomfortable with experimental compounds

Editorial summary for research context · Not medical advice

Mechanism of Action

Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) designed as a liver-tissue bioregulator. Khavinson-group research proposes that short peptides penetrate the cell membrane, enter the nucleus, and bind promoter regions — modulating tissue-specific gene expression in hepatocytes. In-vitro work has also examined chromatin decondensation in lymphocytes. Not FDA-approved. Preclinical and limited human data from Khavinson group.

Researched Benefits

Hepatocyte gene-expression modulation

Khavinson-lab studies report modulation of gene expression in hepatocyte cultures with proposed relevance to age-related hepatic decline.

[Khavinson & Malinin 2005]

Lymphocyte chromatin research

Cell-culture work has examined chromatin decondensation and heterochromatin activation in peripheral lymphocytes following peptide exposure.

[Khavinson et al. 2003]

Research Protocols

The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.

Intranasal research protocol

Dosage: 100 mcg
Frequency: once daily
Timing: morning
Cycle: 3 weeks

Khavinson-group protocols have typically used 20-30 day cycles, repeated 2x per year.

Reported Side Effects

No significant adverse events reported in published Khavinson-group studies
Transient local irritation with intranasal administration
Long-term human safety data limited

Contraindications

Pregnancy and lactation (no safety data)
Active hepatic malignancy (theoretical concern)
Individual hypersensitivity to peptide components

Stacking Partners

Peptides commonly paired with Livagen in published research and protocol write-ups.

bioregulator

Vendor Pricing

75
Swiss Chems
Best $/mg
Size20mg
Total$62.95
/ mg$3.15/mg
In stock
View
72
Limitless Biotech
Size20mg
Total$62.99
/ mg$3.15/mg
In stock
View
75
Iron Peptides
Size20mg
Total$79.99
/ mg$4.00/mg
In stock
View

Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.

Research Papers

Peptide Livagen activates chromatin in old lymphocytes
Khavinson VKh, Lezhava TA, Monaselidze JR · Bulletin of Experimental Biology and Medicine · 2003
Gerontological aspects of peptide regulation
Khavinson VKh, Malinin VV · Karger · 2005

Livagen

Mechanism of Action